Harold L. Dauerman, MD, FACC

Education:

Training:

Residency

Fellowship

Specialty:

Certifications:

Academic Appointments:

Biography:

An expert in cardiac catheterization and percutaneous cardiovascular revascularization techniques, Dr. Dauerman has a broad background in clinical medicine, research, teaching and hospital administration. In addition to his work as a principal investigator on many trials testing the efficacy of diverse invasive cardiology techniques, he has lectured and published widely on invasive cardiology treatment including coronary stenting, acute myocardial infarction and cardiogenic shock. While at the University of Massachusetts, he directed the Interventional Cardiology program and focused on improving quality and timeliness of patient care. These efforts continue in his current position as Director, Cardiovascular Catheterization Laboratories at Fletcher Allen Health Care. A native of the New York area, Dr. Dauerman lives in Shelburne with his wife, who is also a physician, and their two young daughters.

Major Research Interests:

Dr. Dauerman has used both investigator initiated and multi-center registry studies to elucidate optimal interventional cardiology treatment options for high risk patients ,such as those with in-stent restenosis, coronary bifurcation lesions, ST elevation myocardial infarction, and cardiogenic shock. A recent research focus is the identification of cardiac risk after coronary intervention by assessing systemic markers of inflammation.  These results will lead to trials designed to determine the impact of anti-inflammatory treatment on outcomes after coronary intervention.

Current Research Grants

Multicenter Clinical Trials:

EVOLVE Trial: Efficacy of Intraveneous MC-135 as and adjunct to Primary PCI: 2003-2005.

SPIRIT 3: Everolimus versus Taxol drug eluting stents randomized trial: 2005-2006

TRIUMPH: Nitric Oxide inhibition after PCI for Cardiogenic Shock: (Steering Committee): 2005-2007

CORAL National Randomized Trial: Renal stenting versus medical therapy:  2005-2007

SPIRIT IV: Everolimus vs. Taxol DES randomized trial: 2006-2007

Investigator Initiated Studies:

AESIS: Angiographic and Endothelial Study of Inflammation and Stenting: 2003-2005

Major Bifurcation Lesion Registry: Indictations for a Bifurcation Stent: 2005-2006

Pharmacoinvasive Therapy for STEMI: A Multicenter Registry: 2006

Clip Based High Risk Femoral Artery Closure: 2006

Novel Renal and Cardioprotective Angiography Contrast Agent: 2006-07

Publications:

Dauerman HL, Sobel BE. Synergistic treatment of ST segment elevation acute myocardial infarction with pharmacoinvasive recanalization. J Am Coll Cardiol 2003; 42:646-651.

Aggarwal A, Schneider DJ, Sobel BE, Dauerman HL. Temporal differences in inflammation among diabetic patients undergoing coronary stenting. Am J Cardiol 2003; 92:924-929.

Gogo PB, Schneider DJ, Terrien EF, Watkins MW, Sobel BE, Dauerman HL. Relation of leukocytosis to C reactive protein and interleukin 6 among patients undergoing percutaneous coronary intervention. Am J Cardiol  2005; 96:538-542.

Dauerman HL, Yarzebski J, Lessard D, Gore JM, Goldberg RJ.  Anemia predicts bleeding, heart failure and death for patients hospitalized with acute myocardial infarction. Am J Cardiol 2005; 96:1379-1383.

Dauerman HL and Sobel BE, Editors. Pharmacoinvasive Therapy for Acute Myocardial Infarction. New York,  Taylor Francis, 2005.

Aggarwal A, Schneider DJ, Terrien EF, Terrien CM, Sobel BE, Dauerman HL. Comparison of effects of abciximab - vs - eptifibatide on C-reactive protein, interleukin-6, and interleukin-1 receptor antagonist after coronary stenting.  Am J Cardiol 2003; 91:1346-1349.

Aggarwal A, Schneider DJ, Sobel BE, Dauerman HL. Temporal differences in inflammation among diabetic patients undergoing coronary stenting. Am J Cardiol 2003; 92:924-929.

Aggarwal A, Schneider DJ, Terrien EF, Sobel BE, Dauerman HL. Increased coronary arterial release of interleukin-1 receptor antagonist and soluble CD40 ligand indicative of inflammation associated with culprit coronary plaques. Am J Cardiol  2004; 93:6-9.

Gogo PB Jr, Schneider DJ, Terrien EF, Sobel BE, Dauerman HL.  Osteoprotegerin is not associated with angiographic coronary calcification.  J  Thromb Thrombolysis  2006; 22:177-183.

Dauerman HL, Frederick PD, Miller D, French WJ for the National Registry of Myocardial Infarction-5 Investigators.  Current incidence and clinical outcomes of bivalirudin administration among patients undergoing primary coronary intervention for stent thrombosis elevation acute myocardial infarction.  Coron Artery Dis  2007; 18:141-148.